Skip to main content

Table 4 Multivariable cox regression model for DFS

From: Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Gene/Clinical

Comparison

Adjusted DFS

  

HR (95% CI)

Wald P-value

CYP2B6

Any variant vs. All WT

1.06 (0.77, 1.46)

0.72

CYP2C9

Any variant vs. All WT

1.11 (0.80, 1.53)

0.53

CYP2D6

G/A vs. A/A

0.94 (0.46, 1.94)

0.87

 

G/G vs. A/A

0.99 (0.50, 1.99)

0.99

CYP3A4

*1B/*1A vs. *1A/*1A

2.79 (1.52, 5.14)

0.001

 

*1B/*1B vs *1A/*1A

2.67 (0.86, 8.34)

0.09

CYP3A5

*3/*1 vs. *1/*1

1.18 (0.47, 2.98)

0.72

 

*3/*3 vs. *1/*1

2.09 (0.79, 5.50)

0.14

CYP3A5

*6/*1 vs. *1/*1

1.37 (0.39, 4.79)

0.62

GSTM1

Null vs. Non-null

0.78 (0.57, 1.06)

0.12

GSTT1

Null vs. Non-null

1.32 (0.86, 2.01)

0.21

GSTP1

Any Var vs. All WT

0.94 (0.69, 1.28)

0.69

Lymph node

Continuous

1.02 (1.00, 1.04)

0.03

Tumor size

Continuous

1.00 (0.97, 1.01)

0.46

Age

Continuous

0.99 (0.97, 1.01)

0.46

ER

Pos vs. Neg

--

--

PR

Pos vs. Neg

1.01 (0.69, 1.50)

0.95

Race

Black vs. White

1.08 (0.52, 2.25)

0.84

 

Other vs. White

1.84 (0.91, 3.70)

0.09

Arm

CAF+HDC vs. CAF

0.66 (0.48, 0.91)

0.01

  1. CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: hazard ratio; PR: progesterone receptor